Fig 1.
PRISMA flow diagram.
Table 1.
Weighted average of mean and median sCTX according to route of administration and bisphosphonate indication.
Fig 2.
Meta-analysis of the 95th, 97.5th and 99th percentiles of all the included patients with MRONJ.
Fig 3.
Meta-analysis of the 95th, 97.5th and 99th percentiles of the patients with MRONL treated for osteoporosis.
Fig 4.
Bar chart of sCTX levels of all individual values within a) the entire population with MRONJ (n = 58), b) patients treated for osteoporosis (n = 38), c) patients treated for cancer-related conditions (n = 20).
There is a significant dispersion of values within the population of patients with cancer-related conditions, which extends to the entire study cohort. This variability hinders the establishment of a safety threshold against medication-related osteonecrosis of the jaw (MRONJ) in these patients. In the osteoporotic patient group, only two individuals displayed sCTX levels above 200 pg/mL, with none exceeding 270 pg/mL.
Table 2.
sCTX values among patients treated with bisphosphonates who developed MRONJ after oral surgery, with individual data available.